# Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

> **NCT00988507** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 440 (estimated)

## Conditions studied

- Plasmodium Falciparum Infection

## Interventions

- **DRUG:** Ferroquine (SSR97193)
- **DRUG:** Placebo
- **DRUG:** artesunate

## Key facts

- **NCT ID:** NCT00988507
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 440 (ESTIMATED)
- **Why stopped:** Company decision to modify the ferroquine development strategy; discontinuation not due to safety or activity unexpected findings
- **Last updated:** 2011-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00988507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00988507, "Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00988507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*